Products Porfolio &
Fast expending portfolio
Already 4 programs in Preclinical & Clinical
LEAD FORMULATION RESEARCH
PARTNER: BILL & MELINDA GATES FOUNDATION
PRECLINICAL & CLINICAL DEVELOPMENT
mdc-IRM / Schizophrenia • Clinical Phase 3
Central Nervous System
mdc-TJK / CNS • Preclinical & Regulatory
PAIN AND INFLAMMATION
mdc-CWM / Pain & Inflammation • Clinical Phase 2
mdc-CMV / Anesthesia, Pain • Preclinical & Regulatory
As of May, 2019
Favorable risk assessment
All current products under development are based on already approved APIs. When compared to NCEs (New Chemical Entity), use of well-understood, approved APIs is an opportunity to make treatments quickly available with significantly less financial resources needed and less risk in clinical phases.
We have designed a strong procedure to identify LAI opportunities and enlarge our portfolio of proprietary and partnered products. This assessment process aims to identify the unmet needs in a large panel of indications that could be met with LAI and to identify the most compatible APIs with our technology. This preliminary step is essential to increase significantly the likelihood of success for each product entering formulation stage.
with approved APIs
Products based on already approved APIs can benefit from decreased time-to-market thanks to simplified pathways such as the 505(b)2 in the US, while providing all of the benefits from long-acting formulations with controlled release.
with new APIs
There are a fair amount of new therapeutic molecules that could be optimized for long-acting injectable treatments. Our technology could be the empowering entity to APIs that can’t be used in today’s traditional, drug delivery systems, or whose benefits would be limited as a result of toxicity.
We’re always looking for new talent